Evidence map›Paper›PMID 33934544›Full record

ArticleESC heart failure2021

Identification of novel circulating microRNAs in advanced heart failure by next-generation sequencing.

Alessandro Galluzzo, Simona Gallo, Barbara Pardini, Giovanni Birolo, Piero Fariselli, Paolo Boretto, Annapia Vitacolonna, Caterina Peraldo-Neia, Martina Spilinga, Alessandra Volpe and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Alessandro GalluzzoDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0003-2803-6761
Simona GalloDepartment of Oncology, University of Turin, Turin, Italy.ORCID 0000-0001-7404-1356
Barbara PardiniCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.ORCID 0000-0001-9571-4257
Giovanni BiroloDepartment of Medical Sciences, University of Turin, Turin, Italy.
Piero FariselliDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0003-1811-4762
Paolo BorettoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Annapia VitacolonnaDepartment of Oncology, University of Turin, Turin, Italy.ORCID 0000-0002-7492-6100
Caterina Peraldo-NeiaCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.ORCID 0000-0002-5484-2030
Martina SpilingaDepartment of Oncology, University of Turin, Turin, Italy.
Alessandra VolpeDepartment of Medical Sciences, University of Turin, Turin, Italy.
Dario CelentaniDepartment of Medical Sciences, University of Turin, Turin, Italy.
Stefano PidelloDepartment of Medical Sciences, University of Turin, Turin, Italy.
Alessandro BonzanoCandiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Giuseppe MatulloDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0003-0674-7757
Carla GiustettoDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-5102-3398
Serena BergeroneA.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Tiziana CrepaldiDepartment of Oncology, University of Turin, Turin, Italy.ORCID 0000-0003-3410-947X
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITCandiolo Cancer Institute · ITUniversity of Turin · ITFondazione Edo ed Elvo Tempia · ITItalian institute for Genomic Medicine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsRisk stratification in patients with advanced chronic heart failure (HF) is an unmet need. Circulating microRNA (miRNA) levels have been proposed as diagnostic and prognostic biomarkers in several diseases including HF. The aims of the present study were to characterize HF-specific miRNA expression profiles and to identify miRNAs with prognostic value in HF patients. METHODS AND

resultsWe performed a global miRNome analysis using next-generation sequencing in the plasma of 30 advanced chronic HF patients and of matched healthy controls. A small subset of miRNAs was validated by real-time PCR (P < 0.0008). Pearson's correlation analysis was computed between miRNA expression levels and common HF markers. Multivariate prediction models were exploited to evaluate miRNA profiles' prognostic role. Thirty-two miRNAs were found to be dysregulated between the two groups. Six miRNAs (miR-210-3p, miR-22-5p, miR-22-3p, miR-21-3p, miR-339-3p, and miR-125a-5p) significantly correlated with HF biomarkers, among which N-terminal prohormone of brain natriuretic peptide. Inside the cohort of advanced HF population, we identified three miRNAs (miR-125a-5p, miR-10b-5p, and miR-9-5p) altered in HF patients experiencing the primary endpoint of cardiac death, heart transplantation, or mechanical circulatory support implantation when compared with those without clinical events. The three miRNAs added substantial prognostic power to Barcelona Bio-HF score, a multiparametric and validated risk stratification tool for HF (from area under the curve = 0.72 to area under the curve = 0.82).

conclusionsThis discovery study has characterized, for the first time, the advanced chronic HF-specific miRNA expression pattern. We identified a few miRNAs able to improve the prognostic stratification of HF patients based on common clinical and laboratory values. Further studies are needed to validate our results in larger populations.

Indexed as

Circulating MicroRNAHeart FailureMicroRNAsBiomarkersHigh-Throughput Nucleotide SequencingHumansBiomarkersCirculating MicroRNAMicroRNAsBiomarkersCirculating microRNAsHeart failureRisk stratification

Identifiers

PMID33934544
PMCPMC8318428
OpenAlexW3159080725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.